世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

欧州の高リン血症治療薬市場予測 2019-2027年

EUROPE HYPERPHOSPHATEMIA DRUG MARKET FORECAST 2019-2027

 

出版社 出版年月電子版価格 ページ数
Inkwood Research
インクウッドリサーチ
2018年11月US$1,250
シングルユーザライセンス(印刷不可PDF)
81

サマリー

この調査レポートは欧州の高リン血症治療薬市場を分析・予測したInkwood Researchの市場調査報告書です。

Overview

KEY FINDINGS
The Europe hyperphosphatemia drug market is expected to grow at a CAGR of 15.63% during the forecast period of 2019-2027. The market revenue is estimated to increase from $xx million in 2018 to $xx million by the end of 2027. Rising elderly citizenry, altering dietary habits and surging cases of osteoporosis are responsible for the expansion of the hyperphosphatemia drug market.
MARKET INSIGHTS
The Calcium-based phosphate binder’s formulation containing substituted aluminium-based phosphorus binders that act like calcium supplements are expected to dominate the hyperphosphatemia drugs market during the forecast period; with a market share of xx%, as observed in 2018. The other phosphate binders include aluminium-based phosphate binders and magnesium-based phosphate binders that are increasingly being used for treating the hyperphosphatemia conditions in dialysis patients. In spite of such formidable demand of the drug for kidney-related ailments, the market is facing certain constraints because of some limitations levied by the Food and Drug Administration (FDA) and the growing side effects of the available hyperphosphatemia drugs such as lanthanum, sevelamer, and others.

COMPETITIVE INSIGHTS

A majority of companies are focusing on launching formulated hyperphosphatemia drugs. Some of them include Sun Pharm Inc., Keryx Biopharmaceuticals, Zeria Pharmaceutical, Fermenta Biotech Ltd, Bruno Pharmaceutical Spa, Pfizer Inc, DSM Biotech Pharmacal, Roche Diagnostics Corporation, Vifor Pharma, Fresenius Medical Care, Shire Amag Pharmaceuticals, Johnson and Johnson, Ultragenyx, Sanofi, Cipla, and R.H. Moore Drug Co.



 

ページTOPに戻る

あなたが最近チェックしたレポート一覧

  • 最近チェックしたレポートはありません。

お問合は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのお問合せはこちらのフォームから承ります

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

<無料>メルマガに登録する

 

 

ページTOPに戻る